Ruxolitinib CAS 941678-49-5
Factory Supply Ruxolitinib CAS 941678-49-5 with Best Price
- Appearance: White powder
- Assay: 99. 0%min
- Stock: In stock
- Sample: Available
- Zhishang Chemical: Ruxolitinib Supplier & Manufacturer
Ruxolitinib: The Complete Guide
Ruxolitinib for Sale
|Other Name:||Ruxolitinib phosphate; (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile|
|Type:||Pharmaceutical Intermediates; Pharmaceutical raw materials|
What is Ruxolitinib?
Myelofibrosis (MF) is a rare myeloproliferative disorder in which the bone marrow in the body is replaced by mark cells, leading to the production of blood cells in body organs such as the liver and also spleen, characterized by splenomegaly, anemia, leukocyte and Thrombocytopenia, as well as differing degrees of bone sclerosis. Signs include fatigue, abdominal discomfort, discomfort under the ribs, muscle mass as well as bone pain, itching, and also night sweats.
Ruxolitinib is the first oral medicine approved by the US Food and Drug Administration for the treatment of myelofibrosis. It is a tyrosine kinase prevention, a small particle inhibitor of the protein kinases JAK1 and also JAK2, showed for the treatment of intermediate or risky myelofibrosis, including main myelofibrosis, postpolycythemia vera myelofibrosis as well as Myelofibrosis after important thrombocythemia.
On August 29, 2012, the European Union approved the very first drug for the therapy of myelofibrosis – ruxolitinib, ruxolitinib for the treatment of intermediate or risky myelofibrosis, including main myelofibrosis, polycythemia vera Postoperative myelofibrosis and blog post essential thrombocythemia myelofibrosis. Currently, ruxolitinib has been approved by more than 50 countries worldwide, including the European Union, Canada and also some countries in Asia, Latin America as well as South America.
Novartis Pharmaceuticals of the United States has accredited the advancement as well as commercialization legal rights of Ruxolitinib outside the USA from Incyte. Both the European Payment and also the FDA have given Ruxolitinib orphan drug condition for the therapy of myelofibrosis. Presently, Incyte has been sold in the USA under the trade name Jakafi for the therapy of intermediate or risky myelofibrosis.
The mechanism of action of ruxolitinib is mainly to bind to the JAK1 site and inhibit the activation of the entire JAK-STAT channel, thereby targeting and forcibly suppressing the abnormally enhanced signal of the channel, thereby obtaining good clinical efficacy.
In addition to myelofibrosis, ruxolitinib can also treat other myeloproliferative diseases, such as true redness and thrombocytosis.
The Manager has Something to Say
This is William, CEO of Zhishang Chemical Co., Ltd.
Welcome to visit our factory . As the top chemical manufacturer, we have been striving for product quality, innovation , R&D, and customer service for the past 7 years. In the next 10 years or even longer, we are committed to becoming the most reliable chemical supplier in the world , creating a well-known international brand trusted by customers, with the spirit of “one meter wide, ten thousand meters deep”, we continue to focus on product research and development, continue to focus on customer service, continue to improve the supply chain service system, to create a professional chemical supply service team, to achieve win-win long-term cooperation. Please feel free to contact us if you have any questions.
- Email: email@example.com
- Phone: +86 176 5311 3209
- WhatsApp: +86 176 5311 3209
- WeChat: Zhishang17653113209
- Skype: +86 176 5311 3209
If you want to buy ruxolitinib, pls contact us to get a free quote.
Application of Ruxolitinib
Ruxolitinib (additionally referred to as ruxolitinib) is a kinase inhibitor indicated for the therapy of intermediate or high-risk myelofibrosis, consisting of main myelofibrosis, postpolycythemia vera myelofibrosis and main myelofibrosis Clients with post-thrombocytosis myelofibrosis. Ruxolitinib (Jakavi), an oral JAK1 as well as JAK2 tyrosine kinase inhibitor, was approved by the European Union in August 2012 for the treatment of intermediate or risky myelofibrosis, including main myelofibrosis, myelofibrosis after polycythemia vera and myelofibrosis after necessary thrombocythemia.
At present, ruxolitinib Jakavi has actually been accepted by greater than 50 nations worldwide, including the European Union, Canada as well as some nations in Asia, Latin America and also South America. Novartis has licensed the development and also commercialization civil liberties of Ruxolitinib outside the United States from Incyte. Both the European Payment as well as the FDA have actually given Ruxolitinib orphan medicine status for the therapy of myelofibrosis. Currently, Incyte has been marketed in the USA under the trade name Jakafi for the therapy of intermediate or risky myelofibrosis.
How has ruxolitinib influenced the treatment landscape for MF in recent years?
It is currently the only drug approved for the therapy of MF along with Fedratinib (Inrebic). For a long period of time, there was no FDA-approved drug for the therapy of MF that considerably boosted client survival. Nonetheless, ruxolitinib was authorized in 2011. Since then, ruxolitinib has actually transformed the landscape of MF treatment, not only boosting symptoms but likewise extending survival and reducing spleen size. Now, different drug enhancements to ruxolitinib are being examined to enhance end results in MF clients.
The initial researches, the COMFORT-1 and COMFORT-2 research studies in MF, guaranteed excellent patient response when contrasted to finest care or various other encouraging care, as well as subsequent actual renovation. This is helpful for people with polycythemia vera. Recently, sunitinib (Sutent) was accepted for the treatment of severe GvHD and looks very encouraging in persistent GvHD. It has a really unique device for improving inflammation, which is the primary chauffeur in these individuals, whether in MF various other myeloproliferative tumors (MPNs) or GvHD. It has undoubtedly enhanced treatment end results for the client population and also changed the therapy paradigm for MPN and GvHD.
Ruxolitinib Suppliers and Manufacturers
As a ruxolitinib supplier and manufacturer with a strict standard product quality system certificate, Zhishang Chemical has long been providing the best ruxolitinib raw materials to customers all over the world.
Over the years, relying on professional team experience and customer-centric team concept to meet customer needs in a timely manner, our company enjoys a high reputation in the world. At present, our company has served more than 6,000 customers and has established long-term cooperative relations with customers from many countries.
If you have a demand for ruxolitinib and related products, please contact our service staff Zhishang Chemical – White directly, and we will provide you with high-quality products at the best price.
* Prompt reply and 24 hours online, professional team to provide the best price and high-quality product.
* Sample testing support.
* Every batch of products will be tested to ensure its quality.
* The packing also can be according to the customers` requirement.
* Any inquiries will be replied to within 24 hours.
* We provide a Commerical Invoices, Packing Lists, Bills of loading, COA, Health certificates, and Origin certificates. If your markets have any special requirements, let us know.
* The fact of logistics information monitoring.
* Any questions about the product can be consulted at any time.
* Product has any problem can return.